Mark Daniel Benson, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteomics | 11 | 2023 | 3750 | 1.300 |
Why?
|
| Aptamers, Nucleotide | 4 | 2020 | 173 | 1.040 |
Why?
|
| Blood Proteins | 6 | 2020 | 1155 | 0.950 |
Why?
|
| Metabolomics | 5 | 2023 | 1602 | 0.720 |
Why?
|
| SELEX Aptamer Technique | 1 | 2019 | 18 | 0.700 |
Why?
|
| High-Throughput Screening Assays | 3 | 2020 | 930 | 0.510 |
Why?
|
| Proteome | 4 | 2022 | 1818 | 0.370 |
Why?
|
| Peripheral Arterial Disease | 1 | 2022 | 1294 | 0.370 |
Why?
|
| Coronary Artery Disease | 3 | 2022 | 6591 | 0.370 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 15619 | 0.320 |
Why?
|
| Cardiovascular System | 1 | 2016 | 846 | 0.320 |
Why?
|
| Genome-Wide Association Study | 7 | 2023 | 12451 | 0.300 |
Why?
|
| Genetic Variation | 2 | 2020 | 6510 | 0.270 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2021 | 851 | 0.260 |
Why?
|
| Atherosclerosis | 1 | 2021 | 3502 | 0.240 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4520 | 0.230 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 2212 | 0.230 |
Why?
|
| Chemokine CX3CL1 | 1 | 2021 | 63 | 0.190 |
Why?
|
| Quantitative Trait Loci | 2 | 2019 | 2073 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2017 | 1260 | 0.150 |
Why?
|
| Echocardiography | 2 | 2021 | 4949 | 0.150 |
Why?
|
| Teaching Rounds | 1 | 2022 | 275 | 0.150 |
Why?
|
| Heredity | 1 | 2017 | 147 | 0.140 |
Why?
|
| Proteoglycans | 1 | 2020 | 802 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3307 | 0.140 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 387 | 0.140 |
Why?
|
| Coronary Disease | 2 | 2022 | 5996 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 716 | 0.120 |
Why?
|
| Risk Factors | 8 | 2023 | 73418 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 12154 | 0.110 |
Why?
|
| Adipocytes | 1 | 2019 | 1178 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2176 | 0.100 |
Why?
|
| Carotid Artery Diseases | 1 | 2018 | 878 | 0.100 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 976 | 0.100 |
Why?
|
| Heart Failure | 3 | 2021 | 11728 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 1430 | 0.100 |
Why?
|
| Aptamers, Peptide | 2 | 2022 | 28 | 0.100 |
Why?
|
| Humans | 27 | 2023 | 752810 | 0.100 |
Why?
|
| Phenotype | 5 | 2022 | 16440 | 0.090 |
Why?
|
| Databases, Genetic | 1 | 2017 | 1745 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2917 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15146 | 0.080 |
Why?
|
| Myocardium | 2 | 2017 | 4650 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2022 | 6332 | 0.080 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 14323 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 19907 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 15645 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 4705 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2019 | 3910 | 0.070 |
Why?
|
| Incidence | 5 | 2022 | 21162 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2022 | 23785 | 0.060 |
Why?
|
| Middle Aged | 11 | 2022 | 217250 | 0.060 |
Why?
|
| Kidney | 1 | 2020 | 6985 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2017 | 4224 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2017 | 3065 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5840 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 1176 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4071 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2023 | 23235 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 25540 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 166825 | 0.050 |
Why?
|
| Male | 12 | 2022 | 355160 | 0.050 |
Why?
|
| Cholesterol, LDL | 2 | 2022 | 2407 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9355 | 0.050 |
Why?
|
| Homoarginine | 1 | 2021 | 9 | 0.050 |
Why?
|
| Orotic Acid | 1 | 2021 | 23 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 80551 | 0.050 |
Why?
|
| Spermine | 1 | 2021 | 69 | 0.050 |
Why?
|
| Uridine | 1 | 2021 | 139 | 0.050 |
Why?
|
| Polyamines | 1 | 2021 | 131 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 5147 | 0.040 |
Why?
|
| Dipeptidases | 1 | 2019 | 38 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2019 | 57 | 0.040 |
Why?
|
| Cystatin C | 1 | 2021 | 267 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 17650 | 0.040 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2019 | 85 | 0.040 |
Why?
|
| Ribonucleotides | 1 | 2019 | 114 | 0.040 |
Why?
|
| Proline | 1 | 2021 | 456 | 0.040 |
Why?
|
| Follistatin | 1 | 2019 | 138 | 0.040 |
Why?
|
| Norway | 1 | 2020 | 492 | 0.040 |
Why?
|
| Female | 11 | 2022 | 386339 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 158 | 0.040 |
Why?
|
| Aged | 6 | 2022 | 166705 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 676 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2020 | 564 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 465 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 185 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 416 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2019 | 557 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2019 | 617 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 484 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 12455 | 0.030 |
Why?
|
| Lymphokines | 1 | 2019 | 928 | 0.030 |
Why?
|
| Podocytes | 1 | 2020 | 406 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2019 | 589 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 64288 | 0.030 |
Why?
|
| Metabolome | 1 | 2022 | 969 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 586 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 887 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 11829 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2017 | 246 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2022 | 1183 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2016 | 357 | 0.030 |
Why?
|
| Antibodies | 1 | 2022 | 2413 | 0.030 |
Why?
|
| Adult | 7 | 2022 | 217168 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 1692 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 977 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Collagen | 1 | 2021 | 2627 | 0.030 |
Why?
|
| Cholesterol | 1 | 2021 | 2903 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2114 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2021 | 21857 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 2900 | 0.020 |
Why?
|
| United States | 3 | 2022 | 71434 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5073 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2022 | 40996 | 0.020 |
Why?
|
| Risk | 1 | 2021 | 9613 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 2979 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 4286 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10454 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8706 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5144 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2021 | 5444 | 0.020 |
Why?
|
| Acute Disease | 1 | 2017 | 7217 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2018 | 9701 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 6746 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15636 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 53833 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 12869 | 0.010 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 2355 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 21724 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14601 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12802 | 0.010 |
Why?
|
| Hypertension | 1 | 2020 | 8497 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39089 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 29369 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 39885 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 58347 | 0.010 |
Why?
|